Kiora Pharmaceuticals, Inc. (KPRX) has a negative trailing P/E of -1.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 2.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -103.19%, forward earnings yield 38.17%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 57/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -9.7 | -0.89 | -393.39 | 193.63 | - |
| 2017 | -10.4 | 0.27 | -71.26 | 336.97 | - |
| 2018 | -13.7 | 0.20 | 16.62 | 89.88 | - |
| 2019 | -40.4 | 0.79 | 43.32 | 106.80 | - |
| 2020 | -29.7 | 1.41 | 20.94 | 16,893.94 | - |
| 2021 | -9.5 | 2.68 | 8.99 | 0.00 | - |
| 2022 | -1.7 | 0.02 | 1.98 | 0.00 | - |
| 2023 | -0.2 | -0.01 | 0.41 | 0.00 | - |
| 2024 | 3.6 | -0.03 | 0.50 | 0.80 | - |
| 2025 | -0.8 | 0.00 | 0.51 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-906.30 | $669.26K | $-13.34M | -1993.8% |
| 2017 | $-556.17 | $407.52K | $-13.22M | -3243.5% |
| 2018 | $-182.81 | $1.65M | $-10.81M | -654.2% |
| 2019 | $-89.24 | $2.69M | $-7.1M | -264.2% |
| 2020 | $-70.50 | $12.06K | $-8.09M | -67102.9% |
| 2021 | $-68.00 | $0.00 | $-16.39M | - |
| 2022 | $-18.55 | $0.00 | $-13.58M | - |
| 2023 | $-24.25 | $0.00 | $-12.51M | - |
| 2024 | $0.87 | $16.02M | $3.59M | 22.4% |
| 2025 | $-2.64 | $0.00 | $-10.84M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.34 | $-2.34 – $-2.34 | $1.5M | $1.5M – $1.5M | 1 |
| 2027 | $-1.75 | $-1.75 – $-1.75 | $28.78M | $28.78M – $28.78M | 1 |
| 2028 | $-0.40 | $-0.40 – $-0.40 | $22.78M | $22.78M – $22.78M | 1 |
| 2029 | $2.02 | $2.02 – $2.02 | $67.39M | $67.39M – $67.39M | 1 |
| 2030 | $7.28 | $7.28 – $7.28 | $52.9M | $52.9M – $52.9M | 1 |
